Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy.

ABSTRACT: Clinical applications of genomic assessment of thyroid cancers are rapidly evolving. We studied tumor samples from patients with imminently threatening and rare thyroid cancers to identify genomic alterations that might correlate with outcomes and/or be productively therapeutically targetable. Progressive and metastatic, and/or rare, thyroid cancers were studied, 2012 to 2016, at Mayo Clinic sites. The intervention was Foundation One tumor interrogation. Main outcome measures included genomic alterations, patient characteristics, and overall survival. Samples from 55 patients were evaluated: 20 anaplastic thyroid cancers (ATCs) (36%), 25 radioactive iodine-refractory differentiated thyroid cancers (DTCs)/poorly differentiated thyroid cancers (PDTCs) (45%; 14 papillary thyroid cancer [PTCs]

SUBMITTER: Iniguez-Ariza NM 

PROVIDER: S-EPMC7263749 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature